The new website reflects the evolution of the brand since WCCT merged with Medelis in May 2016 to offer U.S. and international clients an expanded depth and breadth of clinical research offerings.
“In addition to our early stage clinical research expertise, we’re now able to provide services from very early in the clinical development process right up until drug and/or device approval, all under one roof,” said Jon Rojas, President of WCCT. “This knowledge and expertise is helping our clients gain efficiencies all along the drug development continuum.”
The combined company offers state-of-the-art clinical research sites and full-service study management for early-stage clinical research and the development of specialized therapies and medicines, along with CRO services for phase II through IV studies in oncology and other therapeutic areas requiring rigorous research standards.
“We believe there is a need in the marketplace for a midsized CRO with the specialization and research capabilities of a big CRO, but without the cost structure and typical headaches that can accompany working with a big CRO,” said David Fox, Executive VP, Client Services. “Together, WCCT and Medelis are continuing our vision of becoming the global leader in the development of specialized medicines and therapies.”
To learn more about our expanded capabilities, visit www.wcct.com.